Required fields are marked with *

Verification code

Imiquimod-d9

{PARAM:[Name]}()
Category Herpes simplex Virus (HSV)
CAS 2712126-48-0
Description Imiquimod-d9 (R 837-d9) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Quotation Now

Product Information

Synonyms Imiquimod-d9|HY-B0180S1|CS-0377646|1-(2-(methyl-d3)propyl-1,1,2,3,3,3-d6)-1H-imidazo[4,5-c]quinolin-4-amine
Molecular Weight 249.36
Molecular Formula C14H16N4
Canonical SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Purity ≥98% (HPLC)
Solubility In vitro:
10 mM in DMSO
Appearance Solid powder
Storage Store at -20°C
Complexity 294
Exact Mass 249.193987241
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs.
In Vivo In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α.
Target Toll-like Receptor (TLR); Autophagy; SARS-CoV; HSV
XLogP3-AA 2.6

TAKE YOUR NEXT STEPS

Get Started With Our Industry Experience And Client-Centric Focus!

Talk to Us

Copyright © 2024 BOC Sciences. All rights reserved.